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The ataxia-telangiectasia mutated and RAD3-related (ATR)
kinase initiates DNA damage signaling pathways in human cells
after DNA damage such as that induced upon exposure to ultra-
violet light by phosphorylatingmany effector proteins including
the checkpoint kinaseChk1.The conventional viewofATRacti-
vation involves a universal signal consisting of genomic regions
of replication protein A-covered single-stranded DNA. How-
ever, there are some indications that the ATR-mediated check-
point canbe activatedbyothermechanisms.Here, using thewell
defined Escherichia coli lac repressor/operator system, we have
found that directly tethering the ATR activator topoisomerase
II-binding protein 1 (TopBP1) to DNA is sufficient to induce
ATR phosphorylation of Chk1 in an in vitro system as well as in
vivo in mammalian cells. In addition, we find synergistic activa-
tion of ATR phosphorylation of Chk1 when the mediator pro-
teinClaspin is also tethered to theDNAwithTopBP1.Together,
these findings indicate that crowding of checkpoint mediator
proteins on DNA is sufficient to activate the ATR kinase.
DNA damage checkpoints delay cell cycle progression in
response to DNA damage to maintain genomic integrity. In
mammalian cells, checkpoint response signaling pathways are
initiated primarily by two large phosphoinositide 3-kinase-re-
lated serine-threonine kinases, ataxia-telangiectasia mutated
(ATM)2 and ATM and RAD3-related (ATR). ATM is activated
mainly, but not exclusively, by double-stranded breaks, and
ATR is activated by ultraviolet (UV) and UV-mimetic chemical
agents as well as other conditions that result in replication fork
stalling. Upon activation, ATR activates the key signal-trans-
ducing kinase Chk1 by phosphorylating it on Ser317 and Ser345
(1, 2), and the mediator protein Claspin is required for the effi-
cient phosphorylation of Chk1 (3–5). ATR activation also
requires topoisomerase II-binding protein 1 (TopBP1), which
has been shown to activate ATR directly in defined systems in
vitro (6–11) as well as in vivo (6, 12).
The current model for ATR activation is as follows. Single-
strandedDNA (ssDNA) generated at sites of DNAdamage dur-
ing repair, transcription, or replication is bound by replication
protein A (RPA), which then recruits ATR through a physical
interaction between RPA and the ATR-binding partner, ATR-
interacting protein (ATRIP). Independently, Rad17-RFC loads
the 9-1-1 (Rad9-Rad1-Hus1) checkpoint complex at primer/
template junctions, where it recruits TopBP1 in the proximity
of ATR. We have previously described an in vitro system that
recapitulates ATR phosphorylation of Chk1 dependent on
RPA-coated ssDNA and TopBP1 (8). However, RPA is not
required for maximal ATR kinase activity in this system when
the ssDNA is replaced with DNA containing bulky DNA base
adducts (9, 10). In fact, we found that TopBP1 binds directly to
damaged DNA and that the DNA binding activity of TopBP1 is
required to confer damaged DNA-dependent activation of
ATR. Thus, we hypothesized that TopBP1 may directly recog-
nize damaged DNA in the cell to activate ATR. It is difficult to
assess the direct contribution of DNA damage in the activation
of ATR because of the large number of cellular processes that
generate ssDNA when DNA damage is encountered (i.e. repli-
cation, transcription, and repair). Therefore, to address the
question of whether direct binding of TopBP1 toDNA can acti-
vate ATR, we have tethered TopBP1 to DNA by fusing TopBP1
to the lac repressor (LacR), which has high binding affinity for
DNA containing the lac operator (LacO) sequence. We find
that in the presence of LacO DNA, LacR-TopBP1 activates
ATRphosphorylation of Chk1 both in vitro and in vivo. In addi-
tion, when LacR-Claspin is also tethered to the DNA it func-
tions synergistically with LacR-TopBP1. These findings indi-
cate that concentrating TopBP1 and Claspin on DNA is
sufficient for Chk1 phosphorylation by ATR.
EXPERIMENTAL PROCEDURES
Antibodies, Reagents, and DNA—Chk1 Ser(P)345 antibodies
were purchased from Cell Signaling Technology (2348),
TopBP1 antibodies were fromMillipore (AB3245), RPA2 anti-
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bodies were from Calbiochem (NA18), and Claspin (sc-48771)
and Chk1 (sc-8408) antibodies were purchased from Santa
Cruz Biotechnology. Isopropyl -D-thiogalactopyranoside
(IPTG) was purchased from Promega (V3955) and was dis-
solved in water. LacO plasmid is a 15-kb plasmid that con-
tains 256 Lac operator repeats cloned into pBluescript (Add-
gene plasmid 17655, named Lac-I-SceI-Tet) (13). The control
plasmid was selected because of its similar size of 14.15 kb
and was generated by cloning the ATR gene into the
pcDNA5-FRT/TO-LacI plasmid.
Plasmid Construction—The lac repressor sequence from
pKM208 (14) (Addgene plasmid 13077) was the template for
PCR with LacI forward oligonucletide (5-GGCCAGATCT-
AAGCTTACCATGCCAGTAACGTTATACGATGTCG-3)
and LacI reverse oligonucleotide (5-GGCCGTCGACGCG-
GCCGCGGTACCAGGCCTGCTAGCGGATCCCACCTTC-
CTCTTCTTCTTGGGTCGGGAAACCTGTCGTGCCAG-
3) which was digested with restriction enzymes HindIII and
XhoI and cloned into these sites of pcDNA5-FRT/TO and
pcDNA3 (Invitrogen). FLAG-TopBP1, FLAG-Claspin-C
(amino acids 679–1332), FLAG-Claspin-FL, FLAG-Claspin 3A
mutants (where amino acids Thr916, Ser945, Ser982 were
mutated to alanine) (11) and FLAG-ATR were subcloned into
the BamHI and NotI sites of these vectors. The fusion proteins
produced from these plasmids contain the following: theN-ter-
minal LacR, which is able to dimerize but not form a tetramer;
a canonical nuclear localization sequence; a FLAG epitope; and
the indicated checkpoint protein.
Purification of Checkpoint Proteins—Native ATR-ATRIP,
GST-TopBP1-His, RPA, and His-Chk1 kinase-dead (His-
Chk1-kd) were all purified as described previously (8, 9, 15).
LacR-TopBP1 and LacR-Claspin-CWTand 3Awere expressed
in 293 FlpIn T-REX cells as described in the manufacturer’s
directions (Invitrogen), and purified with anti-FLAG-agarose
(Sigma) as described previously (16).
Kinase Assays—The procedure was essentially as described
previously (11). Briefly, kinase assay reactions contained 14mM
Hepes, pH 7.9, 30mMKCl, 1.2 mMMgCl2, 0.4 mMATP, 0.3 mM
DTT, 1% glycerol, and 1Mmicrocystin in a 10-l final volume.
Purified ATR-ATRIP (0.25 nM) was incubated in the reaction
buffer for 20 min at 30 °C with 12 nM His-Chk1-kd and the
indicated amounts ofDNAand recombinantTopBP1 andClas-
pin. The reactions were terminated by the addition of SDS-
PAGE loading buffer and separated by 10% SDS-PAGE. Chk1
phosphorylation was detected by immunoblotting using
Ser(P)345 antibodies, and the levels of total Chk1 protein were
subsequently detected by immunoblotting the same mem-
brane. Levels of phosphorylation were quantified using
ImageQuant 5.2 software after scanning the immunoblots. The
highest level of Chk1 phosphorylation in each experiment was
set equal to 100, and the levels of phosphorylated Chk1 in the
other lanes were determined relative to this value. The averages
from at least three independent experiments were graphed, and
the error bars indicate the S.D.
DNA Binding Assay—LacO oligonucleotide 5-TGTGGAA-
TTGTGAGCGCTCACAATTCCACA-3 or control oligo-
nucletide 5-ACACCTTAACACTCGCGAGTGTTAAGG-
TGT-3was 5 end-labeled with -32P by polynucleotide kinase
according to the manufacturer’s instructions (New England
Biolabs), self-annealed, and used in electrophoretic mobility
shift assays (EMSAs). The indicated amounts of LacR-TopBP1
or LacR-Claspin-Cwere preincubated for 90min on ice with or
without 150 M IPTG (concentration in final reactions) and
then further incubated for 30min at room temperature with 10
nM labeled oligonucleotides in 0.5 TBE (25 mM Tris, 25 mM
boric acid, 0.6 mM EDTA), 3% glycerol, and 1 mM DTT. The
reactions were loaded directly onto a 5% w/v polyacrylamide
(30:1 acrylamide:bisacrylamide) gel, cast, and run in 0.5 TBE.
Electrophoresis was carried out for 60 min at 25 mA. After
drying, the gel was analyzed by phosphorimaging.
Cell Lines—NIH2/4 (LacO array-containing NIH3T3 cells)
(13) and NIH3T3 cells were cultured in DMEM-H supple-
mented with 10% fetal calf serum, penicillin/streptomycin, and
L-glutamine. The NIH2/4 cells were also cultured with 100
g/ml hygromycin. For transient expression of LacR fusion
proteins, 1  105 cells in 24-well plates were transfected with
the indicated amount of plasmid using 1.25l of Lipofectamine
2000 (Invitrogen) according to themanufacturer’s instructions.
The cells were harvested 18 h after transfection by rinsing twice
with 1 PBS and lysing with 50 l of SDS sample buffer (62.5
mM Tris-HCl, pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT,
0.01% bromphenol blue). After brief sonication and boiling, 15
l of the sample was loaded onto 10% SDS-PAGE for immuno-
blotting as described above.
RESULTS
Chk1 Phosphorylation byATR Is StimulatedWhenTopBP1 Is
Tethered to DNA in a Defined System—Because we have previ-
ously shown thatDNA stimulatesATRkinase activity in aman-
ner dependent on TopBP1 binding to DNA (9), we reasoned
that when fused to LacR, TopBP1 should stimulate ATR kinase
activity specifically when in the presence of LacO DNA even in
the absence of DNA damage. To test this directly, we purified
LacR-TopBP1 (Fig. 1A) and added it to kinase reactions where
we can analyze the site-specific phosphorylation of Chk1 by
ATR. Fig. 1B shows the results from adding increasing concen-
trations of LacR-TopBP1 to ATR kinase reactions without
DNA (lanes 1–4), with LacO DNA (lanes 5–8), or with control
DNA (lanes 9–12). LacR-TopBP1 stimulates ATR phosphory-
lation of Chk1 in reactions containing the LacO DNA up to
10-fold more than in reactions lacking DNA (compare lanes 8
and 4). The activity is specific for DNA containing the LacO
sequence because an equal concentration of DNA lacking the
LacO repeats does not stimulate ATR kinase activity (lanes
9–12). We observe the highest LacO sequence dependence at
low concentrations of DNA, such as used in this experiment,
where there is a negligible effect of adding DNA lacking LacO
(see Fig. 3B for higher DNA concentrations). Because we have
previously observed an effect of DNA length on the activation
of ATR (10), it is important to note that the LacO-containing
and control DNAs used in this study are of similar size (Fig. 1C).
These data, along with our previous finding that recruitment of
ATR to DNA by TopBP1 bound to bulky base adducts was
sufficient for its activation, lead us to conclude that recruitment
of ATR to DNA by whatever means is sufficient to activate it.
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DNA-tethered TopBP1 and Claspin Synergistically Stimulate
ATR Phosphorylation of Chk1 in a Defined System—Consistent
with data in vivo, we have previously reported that the phos-
phorylation of Chk1 by ATR is highly dependent on Claspin in
vitro (11). Furthermore, a C-terminal fragment of Claspin is
sufficient for its activity in vitro. We, therefore, purified the
C-terminal fragment of Claspin fused to the LacR (Fig. 1A) to
determine whether tethering Claspin to DNA would affect
ATR phosphorylation of Chk1. Fig. 2A shows the results from
adding LacR-Claspin to reactions with or without LacR-
TopBP1 in the presence or absence of LacO-containing DNA.
Under thesemore limiting reaction conditions we only observe
significant ATR kinase activity in reactions containing LacR-
TopBP1, LacR-Claspin, and LacO-containing DNA (lane 8).
The limiting concentration of LacR-TopBP1 used in these reac-
tions is insufficient to activate ATR even in the presence of
LacO DNA (lane 5). Reactions lacking TopBP1 do not have
significant Chk1 phosphorylation even in the presence of LacR-
Claspin and LacODNA (lane 11), suggesting that the dimeriza-
tion of LacR is not simply bringing multiple DNAs together to
activate ATR. These results indicate that LacR-Claspin works
synergistically with LacR-TopBP1 in the ATR-Chk1 kinase
reaction by recruiting the ATR substrate Chk1 in the presence
of LacO-containing DNA and further reinforce the concept
that ATR recruitment to DNA by any means is sufficient to
activate its kinase function.
To measure the specific contribution of tethering Claspin to
DNA to activation of ATR, we added LacR-Claspin to reactions
containing TopBP1 fused to either GST or LacR (Fig. 2B). We
observe 10-fold more Chk1 phosphorylation in reactions con-
taining LacR-Claspin together with LacR-TopBP1 in the pres-
ence of LacO-containing DNA than in the presence of control
DNA (compare lanes 4 and 11). However, in reactions contain-
ing LacR-Claspin togetherwithGST-TopBP1 there is no signif-
icant difference in the kinase activity with or without DNA
containing the LacO sequence (compare lanes 5–7 and 12–14).
Note that a higher concentration of GST-TopBP1 was used in
these reactions so that the signal would be above background.
These results indicate that GST-TopB1 does not function syn-
ergistically with LacR-Claspin and LacO DNA, suggesting that
both checkpointmediatorsmust be co-localized on theDNA to
stimulate ATR phosphorylation of Chk1 effectively.
Mutations in theChk1 binding domain ofClaspin abolish the
ability of Claspin to mediate ATR phosphorylation of Chk1 in
vivo (17) and in vitro (11, 18). We purified mutated LacR-Clas-
pin (3A) (Fig. 1A) to test whether mutations in the Chk1 bind-
ing domain of LacR-Claspin (Thr916, Ser945, Ser982 to alanine)
would disrupt its function in our defined system. Fig. 2C shows
the results from adding increasing amounts of wild-type (WT)
or mutant (3A) LacR-Claspin to reactions containing LacR-
TopBP1 and either LacO or control DNA.We find that there is
up to 10-foldmore Chk1 phosphorylation in reactions contain-
FIGURE 1. Tethering TopBP1 to DNA activates ATR phosphorylation of
Chk1 in a defined system. A, 5 ng of purified LacR-TopBP1 (lane 1), LacR-
Claspin-C WT (lane 2), LacR-Claspin-C 3A (Thr916, Ser945, Ser982 to alanine) (lane
3), and RPA (lane 4) were fractionated by SDS-PAGE and then either stained
with silver (top panels) or Western blotted with the indicated antibodies (bot-
tom panels). B, LacR-TopBP1 (0, 0.125, 0.5, 2 nM) was added to kinase reactions
containing 0.25 nM ATR and 12 nM His-Chk1. Reactions 1– 4 contain no DNA,
reactions 5– 8 contain 3 pM LacO DNA plasmid, and reactions 9 –12 contain 3
pM control DNA plasmid. ATR kinase activity was determined by immunoblot-
ting for phospho-Chk1 and Chk1 as indicated. The graph shows quantitative
analysis of the data. C, LacO and control DNA by ethidium bromide staining
after electrophoresis on a 0.8% agarose gel. 100, 200, 400 ng of LacO DNA
(lanes 2– 4) or control DNA (lanes 5–7), previously linearized by digestion with
the single cutting restriction endonucleases SacI and BamHI, respectively,
were loaded onto the gel. The plasmids were linearized to simplify visualiza-
tion, but linearization does not affect ATR activation in our system.
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ing wild-type LacR-Claspin and LacR-TopBP1with LacODNA
compared with control DNA (lanes 2–4 versus lanes 9–11);
however, there is no significant kinase activity in reactions con-
tainingmutant LacR-Claspin in either condition (lanes 5–7 and
12–14). These results further illustrate the essential function of
Claspin in mediating Chk1 phosphorylation by ATR and the
similarity between our in vitro system and the in vivo reaction.
DNABinding by LacR-TopBP1 and LacR-Claspin Is Required
for the Synergistic Stimulation of ATR Phosphorylation of Chk1
in a Defined System—To confirm further that the synergistic
stimulation of ATR kinase activity is due to the binding of the
LacR fusion proteins to the LacO-containing DNA, we per-
formed the kinase reactions in the presence or absence of IPTG.
The binding of IPTG to LacR reduces its affinity for LacO 1000-
fold (19). We first measured DNA binding by EMSA of LacR-
Claspin andLacR-TopBP1 toDNAoligonucleotides containing
the LacO sequence or to control oligonucleotides in the pres-
ence or absence of IPTG. The results in Fig. 3A indicate that
LacR-Claspin has high affinity for LacO-containing DNA (lane
2) relative to the control DNA (lane 5) and that the DNA bind-
ing is lost in the presence of IPTG (lane 3). Similarly, LacR-
TopBP1 binds to LacO DNA (lanes 6–8), and the binding is
eliminated in the presence of IPTG (lanes 9–11). Therefore, we
performed kinase assays in the presence or absence of the same
concentration of IPTG and found that the synergistic ATR acti-
vation by LacR-TopBP1 and LacR-Claspin in the presence of
LacO-containing DNAwas eliminated in the presence of IPTG
(Fig. 3B, compare lanes 2 and 3with lanes 9 and 10). We added
increasing amounts of DNA to these reactions to assess
whether there were nonspecific effects of adding IPTG to the
kinase reactions. In fact, we do not observe any nonspecific
inhibition of the reactions with the IPTG concentration used in
our experiments (compare lanes 4 and 11, and 7 and 14).
Together, these results indicate that the tethering of TopBP1
and Claspin to DNA is required for the synergistic stimulation
of ATR phosphorylation of Chk1.
Tethering TopBP1 to DNA Induces Chk1 Phosphorylation in
Mammalian Cells—To address the physiological relevance of
the ATR activation we observe when TopBP1 is tethered to
DNA in our in vitro system, we examined the ability of DNA-
tethered TopBP1 to induce Chk1 phosphorylation in mamma-
lian cells.We transiently expressed LacR-TopBP1 in a NIH3T3
cell line that contains the LacO array stably integrated into the
genome, named NIH2/4 (13). Fig. 4A shows results from trans-
fecting these cells with increasing amounts of an expression
vector encoding LacR-TopBP1. At the highest concentration of
FIGURE 2. TopBP1 and Claspin function synergistically to stimulate ATR
phosphorylation of Chk1 when tethered to DNA in a defined system.
A, ATR kinase reactions contained no mediator proteins (lanes 1–3), 0.125 nM
LacR-TopBP1 (lanes 4 – 6), 6 nM LacR-Claspin-C (lanes 10 –12), or both (lanes
7–9). Reactions 1, 4, 7, and 10 contain no DNA (), reactions 2, 5, 8, and 11
contain 3 pM LacO DNA (L), and reactions 3, 6, 9, and 12 contain 3 pM control
DNA (C). B, GST-TopBP1 is not synergistic with LacR-Claspin, indicating that
the mediators must co-localize to stimulate ATR effectively. ATR kinase reac-
tions contained 6 nM LacR-Claspin-C and either 3 pM LacO DNA (lanes 1–7) or
3 pM control DNA (lanes 8 –14), and either no TopBP1 (lanes 1 and 8), 0.0417,
0.125, or 0.375 nM LacR-TopBP1 (lanes 2– 4 and 9 –11), or 0.417, 1.25, or 3.75 nM
GST-TopBP1 (lanes 5–7 and 12–14). C, mutations in the Chk1 binding domain
of LacR-Claspin-C (Thr916, Ser945, Ser982 changed to alanine) abolish its ability
to synergize with LacR-TopBP1 to activate ATR phosphorylation of Chk1. ATR
kinase reactions contained 0.125 nM LacR-TopBP1, 3 pM LacO DNA (lanes 1–7),
or 3 pM control DNA (lanes 8 –14), and either no LacR-Claspin (lanes 1 and 8),
0.7, 2, or 6 nM LacR-Claspin-C WT (lanes 2– 4 and 9 –11), or mutant (3A, lanes
5–7 and 12–14).
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transfected LacR-TopBP1 (where the levels of LacR-TopBP1
are similar to endogenous levels of TopBP1), there is 5-fold
more Chk1 phosphorylation than the control condition in
which cells were transfected with empty vector (compare lanes
5 and 1). Therefore, DNA-tethered TopBP1 activates ATR
phosphorylation of Chk1 in vivo, similar to what we have
observed in vitro.
Tethering Both TopBP1 and Claspin to DNA Results in Syn-
ergistic Induction of Chk1 Phosphorylation inMammalianCells—
Because we observed synergistic effects of tethering both
TopBP1 and Claspin to DNA in our in vitro system, we wanted
to determine whether this synergy could be recapitulated in
vivo. Fig. 4B shows the results from transfecting LacR-Claspin
with or without LacR-TopBP1 in cells containing the LacO
array or in cells without the array. Because transfecting LacO
array-containing cells with sufficiently high concentrations of
LacR-TopBP1-expressing plasmid activates ATR (Fig. 4A), we
transfected a limited amount of LacR-TopBP1 so that therewas
no significant Chk1 phosphorylation in cells expressing LacR-
TopBP1 alone (lane 3). However, co-expressing LacR-Claspin
together with LacR-TopBP1 resulted in 5-fold more Chk1
phosphorylation than either alone (compare lane 4with lanes 2
and 3). Importantly, this effect is only observed in cells contain-
ing the LacO array (lane 4) because we do not detect significant
Chk1 phosphorylation when LacR-TopBP1 and LacR-Claspin
are co-expressed in NIH3T3 control cells that do not have the
LacO array (lane 9). Therefore, as was observed in vitro, crowd-
ingATR onDNAwith two different tethers that are also known
to be an activator (TopBP1) and a mediator (Claspin) is suffi-
cient to activate ATR phosphorylation of Chk1 in vivo.
When Tethered Together on DNAwith TopBP1, the C Termi-
nus of Claspin Is Sufficient for Synergistic Stimulation of Chk1
Phosphorylation, and Mutations Abrogate the Function—We
have observed that a C-terminal fragment of Claspin (amino
acids 679–1332) is sufficient for its function in our in vitro
system and that mutations of three amino acids in the Chk1
binding domain of this fragment (Thr916, Ser945, and Ser982)
abrogate its ability to mediate ATR phosphorylation of Chk1.
We wished to test whether this fragment was also sufficient for
the synergistic effect we observe in vivo and whether the
mutated Claspin was functional. Fig. 4C shows the results from
transfecting NIH2/4 LacO array-containing cells with full-
length LacR-Claspin (-FL) or with the C-terminal fragment
(-C), which is WT or mutated (3A), with or without LacR-
TopBP1. We observe similar levels of Chk1 phosphorylation
when either -FL or -C LacR-Claspin is co-transfected with
LacR-TopBP1 (lanes 7 and 9). Importantly, the Chk1 phosphor-
ylation is 3-fold more than with LacR-TopBP1 alone (lane 6) or
without LacR-TopBP1 (lanes 2 and 4). However, the 3A muta-
tion in the LacR-Claspin-FL (lane 8) or LacR-Claspin-C frag-
ment (lane 10) diminishes the ability of Claspin to function
synergistically with TopBP1 to induce Chk1 phosphorylation.
Therefore, as is the case in vitro, the C terminus of Claspin is
sufficient in vivo for synergistic stimulation of Chk1 phosphor-
ylation when tethered to DNA with TopBP1, and mutations in
the Chk1 binding domain of Claspin abrogate this function.
DISCUSSION
In Fig. 5 we present a summary model for the activation of
Chk1 phosphorylation by ATR upon tethering an activator and
mediator protein to DNA. Here, we report that tethering the
checkpoint activator TopBP1 to DNA is sufficient to activate
ATR phosphorylation of Chk1 both in vitro and in vivo. We
have shown previously that the higher binding affinity of
TopBP1 for damagedDNA results in specific activation of ATR
FIGURE 3. DNA binding by TopBP1 and Claspin is required for the syner-
gistic stimulation of ATR phosphorylation of Chk1 in a defined system.
A, LacR-TopBP1 and LacR-Claspin-C DNA binding in the presence or absence
of IPTG is analyzed by EMSAs. The binding reactions contained 10 nM 32P-
labeled 30-bp LacO DNA (lanes 1–3 and 6 –11) or control DNA (lanes 4 and 5)
and 50 nM LacR-Claspin-C (lanes 2, 3, and 5) or 5 nM, 10 nM, 20 nM LacR-TopBP1
(lanes 6 – 8 and 9 –11). In lanes 3 and 9 –11, the LacR fusion protein was prein-
cubated on ice with IPTG at a final concentration of 150 M. The unbound
DNA is indicated by a gray arrow, and the protein-bound DNA is indicated by
a black arrow. The graph shows quantitative analysis of the data. B, ATR kinase
reactions contained 0.125 nM LacR-TopBP1 and 6 nM LacR-Claspin-C and
either no DNA (lanes 1 and 8), or 3, 12, or 48 pM LacO DNA (lanes 2– 4 and
9 –11), or 3, 12, or 48 pM control DNA (lanes 5–7 and 12–14) without (lanes 1–7)
or with 150 M IPTG (lanes 8 –14).
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in the presence of damaged DNA (9). In the current report, we
have bypassed the requirement for damaged DNA both in vitro
and in vivo by fusing TopBP1 to LacR and using DNA contain-
ing LacR binding sites. The results from our in vivo studies are
somewhat unexpected. It has been reported previously that
overexpressing a fragment of TopBP1 containing the ATR-ac-
tivating domain causes ATR activation in mammalian cells
in the absence of DNA damage (6, 12). However, simply teth-
ering the ATR activating domain of TopBP1 to chromatin by
fusing it to histoneH2Bwas not sufficient to induceChk1 phos-
phorylation in DT40 chicken cells in the absence of DNA dam-
age (20). In our study, LacR-TopBP1 is not overexpressed rela-
tive to endogenous TopBP1 (Fig. 4, A and B); however, it is
highly concentrated on the chromatin because of the repeated
LacO sequence. Thus, there may be a TopBP1 concentration
threshold required for ATR activation. In fact, we do observe
LacR-TopBP1 concentration-dependent activation of Chk1
both in vitro (Fig. 1B) and in vivo (Fig. 4A).
We have found that even though tethering the mediator
Claspin toDNA is insufficient to activate ATRphosphorylation
of Chk1 either in vitro or in vivo, tethering Claspin to the DNA
together with TopBP1 functions synergistically to activate ATR
phosphorylation of Chk1 both in vitro and in vivo. Claspin
increases the affinity of ATR for Chk1 (11). Mutations in the
Chk1 binding domain of Claspin abrogate the phosphorylation
of Chk1 by ATR (17, 18, 21, 22). Here, we report that the same
mutations also abrogate the ability of Claspin to function when
tethered to DNAboth in vitro and in vivo. Interestingly, we find
that the C-terminal half of Claspin is sufficient for the synergis-
tic activation of ATRphosphorylation of Chk1 both in vitro and
in vivo. It is known that theN-terminal half of Claspin has DNA
binding activity (23) and is involved in protein-protein interac-
tions required for chromatin association (24); yet, these
requirements are bypassed when Claspin is tethered to the
DNA.
The lac repressor/operator system has previously been used
to study ATM activation in mammalian cells (25) and activa-
tion of the ATR homolog, Mec1, in yeast cells (26). Tethering
individual mediators in the ATM pathway such as members of
the MRN complex (Mre11-Rad50-Nbs1) or Mdc1 was suffi-
cient to activate ATM in the absence of DNA damage (25). In
yeast, however, checkpoint activation was observed when a
member of the 9-1-1 complex was tethered together with the
Mec1-binding partner Ddc2, but not when either was tethered
alone (26). Here, we show that inmammalian cells, simply teth-
ering the activator of ATR is sufficient to induce the checkpoint
response and that the effect is amplified when the mediator
Claspin is also tethered. Taken together, these studies illustrate
the generality that activation of the cellular DNA damage
response pathways does not require DNA damage but can be
FIGURE 4. Tethering both TopBP1 and Claspin to DNA causes synergistic induction of Chk1 phosphorylation in mammalian cells. A, LacO array-
containing NIH2/4 cells (lanes 1– 6) or control NIH3T3 cells (lanes 7–12) were transfected with 0, 20, 60, 180, or 540 ng of pcDNA3-LacR-TopBP1 plasmid and
empty pcDNA3 plasmid such that all of the transfections had equal amounts of DNA. The cells were lysed 18 h later, and the levels of TopBP1, phospho-Chk1,
and Chk1 were analyzed by immunoblotting as indicated. Quantitation of the amount of Chk1 phosphorylation after transfection is graphed below. As a
positive control, cells were treated for 15 min with 2 mM hydroxyurea (HU) to induce Chk1 phosphorylation (lanes 6 and 12). B, LacO array-containing NIH2/4
cells (lanes 1–5) or NIH3T3 control cells (lanes 6 –10) were transfected with 20 ng of pcDNA3-LacR-TopBP1 (lanes 3, 4, 8, and 9), 50 ng of pcDNA3-LacR-Claspin-FL
(lanes 2, 4, 7, and 9), or treated with hydroxyurea (lanes 5 and 10) as in A. C, LacO array-containing NIH2/4 cells were transfected with 20 ng of
pcDNA3-LacR-TopBP1 (lanes 6 –10), 50 ng of pcDNA3-LacR-Claspin-FL WT (lanes 2 and 7), 50 ng of pcDNA3-LacR-Claspin-FL 3A mutant (lanes 3 and 8), 50 ng
pcDNA3-LacR-Claspin-C WT (lanes 4 and 9), 50 ng pcDNA3-LacR-Claspin-C 3A mutant (lanes 5 and 10) and empty pcDNA3 as in A.
FIGURE 5. Model for activation of phosphorylation of Chk1 by ATR upon tethering the TopBP1 activator and Claspin mediator proteins to DNA.
Tethering the ATR activator TopBP1 to DNA induces cooperative binding of ATR and is sufficient to activate ATR phosphorylation of Chk1 (left), whereas
tethering Claspin alone is not sufficient (middle). Claspin increases the affinity of ATR for Chk1 and thus functions synergistically when tethered to DNA together
with TopBP1 (right). Note that this is an artificial mechanism of crowding-induced activation of ATR-ATRIP favoring the collision between TopBP1/ATR-ATRIP/
Claspin/Chk1. Physiologically relevant modes of regulating the binding equilibria between ATR-ATRIP and mediator/activator proteins and substrates include
direct binding of these proteins to RPA-coated ssDNA, DNA structures or base adducts, repair proteins, and other factors.
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triggered by stable association of checkpoint proteins with
chromatin. For the ATR pathway, there are many potential
mechanisms for achieving stable chromatin association of the
checkpoint proteins, such as by RPA-coated ssDNA, which,
through interactions with ATRIP (27) and the checkpoint
mediator protein Tipin (28), bring ATR and Claspin into close
proximity to one another to facilitate Chk1 phosphorylation.
Similarly, interactions between ATR and DNA repair factors
(29–32) as well as direct binding of checkpoint proteins to
DNA structures such as branched DNA (23) or DNA-contain-
ing bulky adducts (9, 33), may also facilitate activation of the
ATR pathway.
In conclusion, we have found that tethering TopBP1 to DNA
is sufficient to activate ATR phosphorylation of Chk1 both in
vitro and in vivo and that when Claspin is also tethered to the
DNA there is a synergistic effect on ATR activation. Our find-
ings taken together with the in vivo studies with recruiting
ATM by tethering in human cells and recruiting Mec1 by teth-
ering in Saccharomyces cerevisiae, bring into focus that recruit-
ment of phosphoinositide 3-kinase-related serine-threonine
kinases members to chromatin by whatever means is sufficient
to institute checkpoint signaling. We believe this realization
will help definemore generally themechanism bywhich check-
point signaling is activated.
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